Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Considerations for management of fluid dynamic issues associated with thiazolidinediones.

Hollenberg NK.

Am J Med. 2003 Dec 8;115 Suppl 8A:111S-115S. Review.

PMID:
14678876
2.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
3.

Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?

Goltsman I, Khoury EE, Winaver J, Abassi Z.

Pharmacol Ther. 2016 Dec;168:75-97. doi: 10.1016/j.pharmthera.2016.09.007. Epub 2016 Sep 4. Review.

PMID:
27598860
4.

Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes.

Toprani A, Fonseca V.

Diabetes Obes Metab. 2011 Mar;13(3):276-80. doi: 10.1111/j.1463-1326.2010.01348.x. Erratum in: Diabetes Obes Metab. 2012 Apr;14(4):386.

PMID:
21205120
5.

Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population.

Wang CC, Chen WL, Kao TW, Chang YW, Loh CH, Chou CC.

Clin Ther. 2011 Dec;33(12):1904-13. doi: 10.1016/j.clinthera.2011.10.025. Epub 2011 Nov 25. Erratum in: Clin Ther. 2012 Feb;34(2):508. Chou, Chih-Chieh [corrected to Chou, Chin-Chieh].

PMID:
22118894
6.

Effect of thiazolidinediones on body weight in patients with diabetes mellitus.

Fonseca V.

Am J Med. 2003 Dec 8;115 Suppl 8A:42S-48S. Review.

PMID:
14678865
7.

Thiazolidinedione-induced congestive heart failure.

Cheng AY, Fantus IG.

Ann Pharmacother. 2004 May;38(5):817-20. Epub 2004 Mar 23.

PMID:
15039476
8.

Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence?

Patel C, Wyne KL, McGuire DK.

Diab Vasc Dis Res. 2005 May;2(2):61-6. Review.

PMID:
16305060
10.
11.

Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events.

Starner CI, Schafer JA, Heaton AH, Gleason PP.

J Manag Care Pharm. 2008 Jul-Aug;14(6):523-31.

12.

Thiazolidinedione insulin sensitizers and the heart: a tale of two organs?

Buckingham RE, Hanna A.

Diabetes Obes Metab. 2008 Apr;10(4):312-28. doi: 10.1111/j.1463-1326.2006.00700.x. Review.

PMID:
18333890
13.

The patient with diabetes mellitus and heart failure: at-risk issues.

Giles TD.

Am J Med. 2003 Dec 8;115 Suppl 8A:107S-110S. Review.

PMID:
14678875
14.

Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure.

Tang WH, Francis GS, Hoogwerf BJ, Young JB.

J Am Coll Cardiol. 2003 Apr 16;41(8):1394-8.

15.

Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

Lipscombe LL, Gomes T, Lévesque LE, Hux JE, Juurlink DN, Alter DA.

JAMA. 2007 Dec 12;298(22):2634-43.

PMID:
18073359
16.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
17.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
18.

Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.

Vasudevan AR, Balasubramanyam A.

Diabetes Technol Ther. 2004 Dec;6(6):850-63. Review.

PMID:
15684639
19.

Thiazolidinediones and congestive heart failure--exacerbation or new onset of left ventricular dysfunction?

Srivastava PM, Calafiore P, MacIsaac RJ, Hare DL, Jerums G, Burrell LM.

Diabet Med. 2004 Aug;21(8):945-50.

PMID:
15270804

Supplemental Content

Support Center